BioWorld MedTech

March 2, 2011

Deals roundup: Daiichi Sankyo to acquire Plexxikon for nearly $930M

A merger agreement between Daiichi Sakyo (Tokyo) and Plexxikon (Berkeley, California) just shy of $1 billion could lead to better personalized treatments for melanoma patients. (Medical Device Daily) Read More

FDA clears Valeritas' V-Go disposable insulin device

Financings roundup: Medtronic, investors to put $31.4 million into Tengion

Washington roundup: FDA warns surgical instrument maker for unapproved claims

Agreements/contracts: PatientPoint to access MZI's EZ-Cap technology

MDD's food for med-tech thought

Court Report: Align files patent infringement suit against rival ClearCorrect

HIT roundup: HealthFirst TPA launches VIIAD products into its offerings

Grants roundup: OZ to provide newborn screening to TEHDI

Product Briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...